Disease-relevant proteostasis regulation of cystic fibrosis transmembrane conductance regulator

Cell Death and Differentiation

Volumn 20, Issue 8, 2013, Pages 1101-1115

  Villella, V R ^a   Esposito, S ^a   Bruscia, E M ^a,b   Vicinanza, M ^c   Cenci, S ^a   Guido, S ^d   Pettoello Mantovani, M ^e   Carnuccio, R ^d   De Matteis, M A ^c   Luini, A ^c,f   Maiuri, M C ^d,g   Raia, V ^d   Kroemer, G ^g,h,i,j   Maiuri, L ^a,e  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c TELETHON INSTITUTE OF GENETICS AND MEDICINE TIGEM   (Italy)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^e UNIVERSITY OF FOGGIA   (Italy)

^f INSTITUTE OF PROTEIN BIOCHEMISTRY   (Italy)

^g INSTITUT GUSTAVE ROUSSY   (France)

^h UNIVERSITÉ PARIS DESCARTES   (France)

ⁱ CENTRE DE RECHERCHE DES CORDELIERS   (France)

^j HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

more..

Author keywords

CFTR; Conformational diseases; Protein trafficking; Proteostasis; SQSTM1

Indexed keywords

BECLIN 1; CYSTAMINE; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; EARLY ENDOSOME ANTIGEN 1; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 PHOSPHATE; PROTEIN P62; RAB PROTEIN; RAB7 PROTEIN; SMALL INTERFERING RNA; TRANSFERRIN RECEPTOR; UVOMORULIN;

AGGRESOME; ARTICLE; AUTOPHAGOSOME; BIOTINYLATION; CAUCASIAN; CELL FRACTIONATION; CELL MEMBRANE; CELL MIGRATION; CELL SURFACE; CONTROLLED STUDY; CYSTIC FIBROSIS; CYTOPLASM VESICLE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HYPOTHESIS; IMMUNOPRECIPITATION; LUNG ALVEOLUS EPITHELIUM; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN HOMEOSTASIS; RNA INTERFERENCE; UBIQUITINATION; WILD TYPE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; APOPTOSIS REGULATORY PROTEINS; BRONCHI; CELL LINE; CELL MEMBRANE; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; EPITHELIAL CELLS; HUMANS; MEMBRANE PROTEINS; MUTATION; PHOSPHORIC MONOESTER HYDROLASES; PROTEOSTASIS DEFICIENCIES; RAB5 GTP-BINDING PROTEINS; RECEPTORS, TRANSFERRIN;

EID: 84880315537     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2013.46     Document Type: Article

References (63)

1. Powers ET, Morimoto RI, Dillin A, Kelly JW, Balch WE. Biological and chemical approaches to diseases of proteostasis deficiency. Annu Rev Biochem 2009; 78: 959-991.
2. Hutt DM, Powers ET, Balch WE. The proteostasis boundary in misfolding diseases of membrane traffic. FEBS Lett 2009; 583: 2639-2646.
3. Roth DM, Balch WE. Modeling general proteostasis: proteome balance in health and disease. Curr Opin Cell Biol 2011; 23: 126-134.
4. Gidalevitz T, Kikis EA, Morimoto RI. A cellular perspective on conformational disease: the role of genetic background and proteostasis networks. Curr Opin Struct Biol 2010; 20: 23-32.
5. Balch WE, Morimoto RI, Dillin A, Kelly JW. Adapting proteostasis for disease intervention. Science 2008; 319: 916-919.
6. Balch WE, Roth DM, Hutt DM. Emergent properties of proteostasis in managing cystic fibrosis. Cold Spring Harb Perspect Biol 2011; 3: a004499.
7. Okiyoneda T, Apaja PM, Lukacs GL. Protein quality control at the plasma membrane. Curr Opin Cell Biol 2011; 23: 483-491.
8. Amaral MD. Targeting CFTR: how to treat cystic fibrosis by CFTR-repairing therapies. Curr Drug Targets 2011; 12: 683-693.
9. O'Sullivan BP, Freedman SD. Cystic fibrosis. Lancet 2009; 373: 1891-1904.
10. Rowe SM, Miller S, Sorscher EJ. Cystic fibrosis. N Engl J Med 2005; 352: 1992-2001.
11. Accurso FJ. Update in cystic fibrosis 2005. Am J Respir Crit Care Med 2006; 173: 944-947.
12. Park HW, Nam JH, Kim JY, Namkung W, Yoon JS, Lee JS et al. Dynamic regulation of CFTR bicarbonate permeability by [Cl-]i and its role in pancreatic bicarbonate secretion. Gastroenterology 2010; 139: 620-631.
13. Welsh MJ, Smith AE. Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell 1993; 73: 1251-1254.
14. Bobadilla JL, Macek M, Fine JP, Farrell PM. Cystic fibrosis: a worldwide analysis of CFTR mutations-correlation with incidence data and application to screening. Hum Mutat 2002; 19: 575-606.
15. Kartner N, Augustinas O, Jensen TJ, Naismith AL, Riordan Jr. Mislocalization of delta F508 CFTR in cystic fibrosis sweat gland. Nat Genet 1992; 1: 321-327.
16. Okiyoneda T, Lukacs GL. Cell surface dynamics of CFTR: the ins and outs. Biochim Biophys Acta 2007; 1773: 476-479.
17. Pedemonte N. Small-molecule correctors of defective [Delta]F508-CFTR cellular processing identified by high-throughput screening. J Clin Invest 2005; 115: 2564-2571.
18. Galietta LJ, Springsteel MF, Eda M, Niedzinski EJ, By K, Haddadin MJ et al. Novel CFTR chloride channel activators identified by screening of combinatorial libraries based on flavone and benzoquinolizinium lead compounds. J Biol Chem 2001; 276: 19723-19728.
19. Van Goor F, Straley KS, Cao D, Gonzá lez J, Hadida S, Hazlewood A et al. Rescue of DeltaF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules. Am J Physiol Lung Cell Mol Physiol 2006; 290: L1117-L1130.
20. Van Goor F, Hadida S, Grootenhuis PD, Burton B, Stack JH, Straley KS et al. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc Natl Acad Sci USA 2011; 108: 18843-18848.
21. Denning GM, Anderson MP, Amara JF, Marshall J, Smith AE, Welsh MJ. Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive. Nature 1992; 358: 761-764.
22. Okiyoneda T, Barriere H, Bagdany M, Rabeh WM, Du K, Hohfeld J et al. Peripheral protein quality control removes unfolded CFTR from the plasma membrane. Science 2010; 329: 805-810.
23. Lukacs GL, Verkman AS. CFTR: folding, misfolding and correcting the DeltaF508 conformational defect. Trends Mol Med 2012; 18: 81-91.
24. Luciani A, Villella VR, Esposito S, Brunetti-Pierri N, Medina D, Settembre C et al. Defective CFTR induces aggresome formation and lung inflammation in cystic fibrosis through ROSmediated autophagy inhibition. Nat Cell Biol 2010; 12: 863-875.
25. Luciani A. SUMOylation of tissue transglutaminase as link between oxidative stress and inflammation. J Immunol 2009; 183: 2775-2784.
26. Maiuri L, Luciani A, Giardino I, Raia V, Villella VR, D'Apolito M et al. Tissue transglutaminase activation modulates inflammation in cystic fibrosis via PPAR gamma down-regulation. J Immunol 2008; 180: 7697-7705.
27. Luciani A, Villella VR, Esposito S, Gavina M, Russo I, Silano M et al. Targeting autophagy as a novel strategy for facilitating the therapeutic action of potentiators on DF508 cystic fibrosis transmembrane conductance regulator. Autophagy 2012; 8: 1657-1672.
28. Poteryaev D, Datta S, Ackema K, Zerial M, Spang A. Identification of the switch in early-tolate endosome transition. Cell 2010; 141: 497-508.
29. Cabrera M, Ungermann C. Guiding endosomal maturation. Cell 2010; 141: 404-406.
30. Rink J, Ghigo E, Kalaidzidis Y, Zerial M. Rab conversion as a mechanism of progression from early to late endosomes. Cell 2005; 122: 735-749.
31. Ravikumar B, Imarisio S, Sarkar S, O'Kane CJ, Rubinsztein DC. Rab5 modulates aggregation and toxicity of mutant huntingtin through macroautophagy in cell and fly models of Huntington disease. J Cell Sci 2008; 121: 1649-1660.
32. Thoresen SB, Pedersen NM, Liestol K, Stenmark H. A phosphatidylinositol 3-kinase class III sub-complex containing VPS15, VPS34, Beclin 1, UVRAG and BIF-1 regulates cytokinesis and degradative endocytic traffic. Exp Cell Res 2010; 316: 3368-3378.
33. Christoforidis S, Miaczynska M, Ashman K, Wilm M, Zhao L, Yip SC et al. Phosphatidylinositol- 3-OH kinases are Rab5 effectors. Nat Cell Biol 1999; 1: 249-252.
34. Simonsen A, Gaullier JM, D'Arrigo A, Stenmark H. The Rab5 effector EEA1 interacts directly with syntaxin-6. J Biol Chem 1999; 274: 28857-28860.
35. Hayakawa A, Hayes SJ, Lawe DC, Sudharshan E, Tuft R, Fogarty K et al. Structural basis for endosomal targeting by FYVE domains. J Biol Chem 2004; 279: 5958-5966.
36. Gillooly DJ, Morrow IC, Lindsay M, Gould R, Bryant NJ, Gaullier JM et al. Localization of phosphatidylinositol 3-phosphate in yeast and mammalian cells. EMBO J 2000; 19: 4577-4588.
37. Raiborg C, Bremnes B, Mehlum A, Gillooly DJ, D'Arrigo A, Stang E et al. FYVE and coiledcoil domains determine the specific localisation of Hrs to early endosomes. J Cell Sci 2001; 114: 2255-2263.
38. Hu Y, Chuang JZ, Xu K, McGraw TG, Sung CH. SARA, a FYVE domain protein, affects Rab5-mediated endocytosis. J Cell Sci 2002; 115: 4755-4763.
39. Sinha S, Levine B. The autophagy effector Beclin 1: a novel BH3-only protein. Oncogene 2008; 27: S137-S148.
40. Kroemer G, Marino G, Levine B. Autophagy and the integrated stress response. Mol Cell 2010; 40: 280-293.
41. Kirkin V, McEwan DG, Novak I, Dikic I. A role for ubiquitin in selective autophagy. Mol Cell 2009; 34: 259-269.
42. Moscat J, Diaz-Meco MT. p62 at the crossroads of autophagy, apoptosis, and cancer. Cell 2009; 137: 1001-1004.
43. Korolchuk VI, Mansilla A, Menzies FM, Rubinsztein DC. Autophagy inhibition compromises degradation of ubiquitin-proteasome pathway substrates. Mol Cell 2009; 33: 517-527.
44. Maxfield FR, McGraw TE. Endocytic recycling. Nat Rev Mol Cell Biol 2004; 5: 121-132.
45. Scita G, Di Fiore PP. The endocytic matrix. Nature 2010; 463: 464-473.
46. Vicinanza M, Di Campli A, Polishchuk E, Santoro M, Di Tullio G, Godi A et al. OCRL controls trafficking through early endosomes via PtdIns4,5P(2)- dependent regulation of endosomal actin. EMBO J 2011; 30: 4970-4985.
47. Daniele T, Di Tullio G, Santoro M, Turacchio G, De Matteis MA. ARAP1 regulates EGF receptor trafficking and signalling. Traffic 2008; 9: 2221-2235.
48. Kelly M, Trudel S, Brouillard F, Bouillaud F, Colas J, Nguyen-Khoa T et al. Cystic fibrosis transmembrane regulator inhibitors CFTR(inh)-172 and GlyH-101 target mitochondrial functions, independently of chloride channel inhibition. J Pharmacol Exp Ther 2010; 333: 60-69.
49. Ma T, Thiagarajah JR, Yang H, Sonawane ND, Folli C, Galietta LJ et al. Thiazolidinone CFTR inhibitor identified by high-throughput screening blocks cholera toxin-induced intestinal fluid secretion. J Clin Invest 2002; 110: 1651-1658.
50. Baudouin-Legros M, Colas J, Moriceau S, Kelly M, Planelles G, Edelman A et al. Long-term CFTR inhibition modulates 15d-prostaglandin J2 in human pulmonary cells. Int J Biochem Cell Biol 2012; 44: 1009-1018.
51. Liang C. Beclin1-binding UVRAG targets the class C Vps complex to coordinate autophagosome maturation and endocytic trafficking. Nat Cell Biol 2008; 10: 776-787.
52. Cholon DM, O'Neal WK, Randell SH, Riordan JR, Gentzsch M. Modulation of endocytic trafficking and apical stability of CFTR in primary human airway epithelial cultures. Am J Physiol Lung Cell Mol Physiol 2010; 298: L304-L314.
53. Silvis MR, Bertrand CA, Ameen N, Golin-Bisello F, Butterworth MB, Frizzell RA et al. Rab11b regulates the apical recycling of the cystic fibrosis transmembrane conductance regulator in polarized intestinal epithelial cells. Mol Biol Cell 2009; 20: 2337-2350.
54. Sharma M, Pampinella F, Nemes C, Benharouga M, So J, Du K et al. Misfolding diverts CFTR from recycling to degradation: quality control at early endosomes. J Cell Biol 2004; 164: 923-933.
55. Samuels IS, Seibenhener ML, Neidigh KB, Wooten MW. Nerve growth factor stimulates the interaction of ZIP/p62 with atypical protein kinase C and targets endosomal localization: evidence for regulation of nerve growth factor-induced differentiation. J Cell Biochem 2001; 82: 452-466.
56. Geetha T, Wooten MW. TrkA receptor endolysosomal degradation is both ubiquitin and proteasome dependent. Traffic 2008; 9: 1146-1156.
57. Delaney SJ, Rich DP, Thomson SA, Hargrave MR, Lovelock PK, Welsh MJ et al. Cystic fibrosis transmembrane conductance regulator splice variants are not conserved and fail to produce chloride channels. Nat Genet 1993; 4: 426-431.
58. Korolchuk VI, Menzies FM, Rubinsztein DC. Mechanisms of cross-talk between the ubiquitinproteasome and autophagy-lysosome systems. FEBS Lett 2010; 584: 1393-1398.
59. Hocking LJ, Mellis DJ, McCabe PS, Helfrich MH, Rogers MJ. Functional interaction between sequestosome-1/p62 and autophagy-linked FYVE-containing protein WDFY3 in human osteoclasts. Biochem Biophys Res Commun 2010; 402: 543-548.
60. Caohuy H, Jozwik C, Pollard HB. Rescue of [Delta]F508-CFTR by the SGK1/Nedd4-2 signaling pathway. J Biol Chem 2009; 284: 25241-25253.
61. Aniento F, Emans N, Griffiths G, Gruenberg J. Cytoplasmic dynein-dependent vesicular transport from early to late endosomes. J Cell Biol 1993; 123: 1373-1387.
62. Maiuri L, Luciani A, Villella VR, Vasaturo A, Giardino I, Pettoello-Mantovani M et al. Lysosomal accumulation of gliadin p31-43 peptide induces oxidative stress and tissue transglutaminase-mediated PPAR gamma downregulation in intestinal epithelial cells and coeliac mucosa. Gut 2010; 59: 311-319.
63. Verkman AS, Galietta LJ. Chloride channels as drug targets. Nat Rev Drug Discov 2009 8: 153-171. Fibrosis Association Nazionale Ricerca (ANR)